Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EPS (Basic) (2016 - 2025)

Sangamo Therapeutics has reported EPS (Basic) over the past 16 years, most recently at -$0.11 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 8.33% year-over-year to -$0.11; the TTM value through Dec 2025 reached -$0.44, up 15.38%, while the annual FY2025 figure was -$0.44, 10.2% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.11 at Sangamo Therapeutics, roughly flat from -$0.11 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.13 in Q1 2023 and troughed at -$0.66 in Q2 2023.
  • A 5-year average of -$0.25 and a median of -$0.28 in 2022 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): plummeted 3200.0% in 2021 and later soared 143.33% in 2023.
  • Year by year, EPS (Basic) stood at -$0.25 in 2021, then dropped by 28.0% to -$0.32 in 2022, then dropped by 6.25% to -$0.34 in 2023, then skyrocketed by 64.71% to -$0.12 in 2024, then increased by 8.33% to -$0.11 in 2025.
  • Business Quant data shows EPS (Basic) for SGMO at -$0.11 in Q4 2025, -$0.11 in Q3 2025, and -$0.08 in Q2 2025.